Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Cantor Fitzgerald
Daiichi Sankyo
Argus Health

Generated: October 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,324,189

« Back to Dashboard

Which drugs does patent 8,324,189 protect, and when does it expire?

Patent 8,324,189 protects ZOMETA and is included in one NDA. There have been two Paragraph IV challenges on Zometa.

Protection for ZOMETA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,324,189

Title:Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Abstract: A method of intravenously administering a bisphosphonate to a patient in need of bisphosphonate treatment comprising intravenously administering 4 mg of 2-(imidazol-1yl)-1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or a pharmaceutically acceptable salt thereof over a period of 15 minutes to a patient in need of said treatment.
Inventor(s): Galli; Bruno (Seltisberg, CH), Schran; Horst F (Morristown, NJ), Seaman; John J (New Hope, PA)
Assignee: Novartis Pharmaceuticals Corporation (East Hanover, NJ)
Application Number:11/594,410
Patent Claim Types:
see list of patent claims
Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
zoledronic acid
INJECTABLE;IV (INFUSION)021223-002Mar 7, 2003APRXYesYes► Subscribe► SubscribeY
zoledronic acid
INJECTABLE;IV (INFUSION)021223-003Jun 17, 2011APRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
Daiichi Sankyo
US Department of Justice
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus